Bio-Rad HIV test recall
This article was originally published in The Gray Sheet
Executive SummarySingle lot of microwell plates performing outside expected ranges for the Genetic Systems HIV-1/HIV-2 peptide EIA qualified enzyme immunoassays test kits spawns recall, CBER announces Oct. 3. Detecting antibodies in human serum and plasma, the tests screen blood and blood products intended for transfusion or further manufacture into plasma products. Consignees are asked to contact the manufacturer to arrange for product return...
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.